Journal: bioRxiv

Article Title: Inhibition of EGFR/ErbB does not protect against C. difficile toxin B

doi: 10.1101/2024.05.13.594035

Figure Lengend Snippet: HT-29 and Caco2 human adenocarcinoma cells are not protected from TcdB by lapatinib pretreatment. A) Immunofluorescent staining of HT-29 cells treated with TcdB (10 nM) for 15-120 minutes shows phosphorylation of EGFR at tyrosine Y1173 and localization of TcdB. Epidermal growth factor (EGF) is used as a positive control. B, C) Cell viability assays for HT-29 and Caco2 cells using CellTiter-Glo show lapatinib does not protect cells from TcdB. Within any given TcdB concentration, there was no significant difference (adjusted p -value < 0.05) between lapatinib and vehicle or between different lapatinib concentrations as measured by one-way Kruskal-Wallis with Dunn’s post-hoc test for multiple comparisons and Bonferroni correction.

Article Snippet: Cells were pretreated with small molecule inhibitors lapatinib or dasatinib (Tocris) dissolved in 1% dimethyl sulfoxide and 99% Dubelco’s Modified Eagle Medium (DMEM).

Techniques: Staining, Positive Control, Concentration Assay

Journal: bioRxiv

Article Title: Inhibition of EGFR/ErbB does not protect against C. difficile toxin B

doi: 10.1101/2024.05.13.594035

Figure Lengend Snippet: Lapatinib pretreatment does not protect normal human colonoids from TcdB-mediated cell death. A) Phase contrast light microscopy images show normal human colonoids are killed by TcdB (1 nM), but they are not protected by lapatinib (2 μM) given 1 h before TcdB; scale bar = 50 μm. B) Quantification of the colonoid experiment in (A) using a range of lapatinib concentrations. C) CellTiter-Glo viability assays with normal human colonoids, lapatinib pretreatment, and lower concentrations of TcdB (10-20 pM). D) CellTiter-Glo viability assay using dasatinib (30 μM) pretreatment, which does not protect colonoids from 20 pM TcdB.

Article Snippet: Cells were pretreated with small molecule inhibitors lapatinib or dasatinib (Tocris) dissolved in 1% dimethyl sulfoxide and 99% Dubelco’s Modified Eagle Medium (DMEM).

Techniques: Light Microscopy, Viability Assay

Journal: Pharmaceutics

Article Title: Recent Progress in Extracellular Vesicle-Based Carriers for Targeted Drug Delivery in Cancer Therapy

doi: 10.3390/pharmaceutics15071902

Figure Lengend Snippet: EVs as nanovectors for therapeutic agents.

Article Snippet: , Lapatinib , MCF10 A , Exosome , Electroporation , Activates T cells and increases their killing ability , Breast cancer , [ ] .

Techniques: Electroporation, Transfection, Activation Assay, Infection, Migration, Incubation, CRISPR, Sonication